Results 21 to 30 of about 15,616 (165)

Case report: Secondary sclerosing cholangitis induced by lapatinib and vinorelbine in a metastasis breast cancer patient

Thoracic Cancer, 2021
Secondary sclerosing cholangitis (SSC) is a rare cholestatic liver disease that may have a severe clinical course. A 61‐year‐old woman with a history of metastasis breast cancer was admitted to our hospital for the second cycle of chemotherapy with ...
Zhuo Zhang, Ling Xu, Naishan Qin, Jixin Zhang, Qian Xiang, Qian Liu, Yuanjia Cheng, Yuge Bai, Qianxin Liu, Yinhua Liu, Xuening Duan, Yimin Cui   +11 more
doaj   +1 more source

Chemotherapy in frail elderly patients with hormone-refractory prostate cancer: A “real world” experience

Prostate International, 2016
Background: In elderly patients affected by metastatic castration-resistant prostate cancer (mCRPC) chemotherapic treatment may be the choice if one considers not only the chronological age, but also the clinical status, the functional reserve, and the ...
Paolo Tralongo, Sebastiano Bordonaro, Annamaria Di Mari, Francesco Cappuccio, Sebastiano Rametta Giuliano   +4 more
doaj   +1 more source

The Role of Reirradiation in Childhood Progressive Diffuse Intrinsic Pontine Glioma (DIPG): An Ongoing Challenge beyond Radiobiology

Brain Sciences, 2023
To investigate the clinical impact of multiple courses of irradiation on pediatric patients with progressive diffuse intrinsic pontine glioma (DIPG), we conducted a retrospective case series on three children treated at our institution from 2018 to 2022.
Maria Chiara Lo Greco, Roberto Milazzotto, Rocco Luca Emanuele Liardo, Pietro Valerio Foti, Stefano Palmucci, Antonio Basile, Stefano Pergolizzi, Corrado Spatola   +7 more
doaj   +1 more source

Use of Metronomic Chemotherapy in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: A Retrospective Multicenter Study. [PDF]

Cancer Med
ABSTRACT Purpose The optimal chemotherapy strategy after progression on cyclin‐dependent kinase 4/6 inhibitors (CDK4/6i) in hormone receptor‐positive/human epidermal growth factor receptor 2‐negative (HR+/HER2−) metastatic breast cancer remains a matter of controversy.
Laini L, Cosentini D, Laganà M, Grisanti S, Scartabellati G, Fogazzi G, Strazzeri S, Amoroso V, Schivardi G, Pedersini R, Berruti A, Turla A.   +11 more
europepmc   +2 more sources

A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer

Thoracic Cancer, 2023
Background This single‐arm prospective phase II trial was performed to assess the efficacy and safety of the dual oral metronomic vinorelbine and capecitabine (mNC) regimen in women with HER2‐negative metastatic breast cancer (MBC) in China.
Yue Chai, Jiaxuan Liu, Mingxia Jiang, Maiyue He, Zijing Wang, Fei Ma, Jiayu Wang, Peng Yuan, Yang Luo, Binghe Xu, Qiao Li   +10 more
doaj   +1 more source

Vinorelbine as First-Line Treatment in Stage IV Canine Primary Pulmonary Carcinoma

Veterinary Sciences, 2023
Vinorelbine (VRL), a semi-synthetic vinca alkaloid commonly used in humans with advanced lung cancer, reaches high concentrations in the lung tissue, has proven antineoplastic activity and a low toxicity profile in dogs.
Valentina Rinaldi, Riccardo Finotello, Andrea Boari, Emanuele Cabibbo, Paolo Emidio Crisi   +4 more
doaj   +1 more source

Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis

Future Science OA, 2021
A retrospective analysis of 70 patients with triple-negative or hormone-resistant advanced breast carcinoma who had not previously received chemotherapy was carried out.
Maria Rosaria Valerio, Pietro Spadaro, Concetta Arcanà, Nicolò Borsellino, Calogero Cipolla, Paolo Vigneri, Dario Piazza, Vittorio Gebbia   +7 more
doaj   +1 more source

Anti-tumor effects of low-dose metronomic vinorelbine in combination with alpelisib in breast cancer cells

EXCLI Journal : Experimental and Clinical Sciences, 2023
In metastatic breast cancer (MBC), PIK3CA mutations, activating the phosphatidylinositol 3-kinase (PI3K) signaling pathway seem to be associated with chemotherapy resistance and poor outcome.
Slavomir Krajnak, Jannis Patrik Trier, Pauline Friederike Heinzmann, Katharina Anic, Anne-Sophie Heimes, Amelie Loewe, Marcus Schmidt, Marco Johannes Battista, Annette Hasenburg, Walburgis Brenner   +9 more
doaj   +1 more source

Intrapatient tumour heterogeneity and clonal evolution in an autopsy study of metastatic salivary gland cancer

Molecular Oncology, EarlyView.
Tumour heterogeneity and clonal evolution of metastatic salivary gland cancer were evaluated in two patients with adenoid carcinoma and one patient with myoepithelial carcinoma. Radiology‐guided autopsy enabled multi‐region sampling (total samples n = 149), followed by whole‐genome sequencing and phylogenetic reconstruction (17 tumour samples, 4–7 per ...
Gerben Lassche, Niels J. van Ruitenbeek, Charlotte Adang, Luke O'Gorman, Pui Yuen Lee, Willemijn M. Klein, Adriana C. H. van Engen‐van Grunsven, Jack A. Schalken, Sander Bervoets, Gerald W. Verhaegh, Carla M. L. van Herpen   +10 more
wiley   +1 more source

Identification of YAP regulators through high-throughput screening and NanoBiT-based validation-drug repositioning for cancer therapy

Animal Cells and Systems
Yes-associated protein (YAP), a key co-transcription factor of the Hippo pathway, is a promising drug target for cancer therapy due to its critical role in promoting cell proliferation, survival, and tumor progression when dysregulated.
Ji-Youn Lim, Eui-Hwan Choi, Yujeong Kim, Minseong Kim, Dongkyu Choi, Wantae Kim, Boksik Cha   +6 more
doaj   +1 more source